LD-2 disclosure · 2nd Quarter - Amendment
EDWARDS LIFESCIENCES LLC
Client
- Location
- California · United States of America
Registrant
- Description
- Medical device manufacturer
- Location
- Irvine, California, United States of America
Lobbying activities
6 issuesHealth Issues
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Lobbyistsms ELIZABETH RAYE KEGLER · BILLY RAINES ii · BRIAN LOOSER
Covered position (BRIAN LOOSER): Pol. Ad. (Sen. Bill Cassidy, LA) LD (Rep. John Shimkus, IL-15) Sr Policy Advisor (Sen. Mark Kirk, IL) LA (Rep. Judy Biggert, IL-13) Leg. Corr./LA (Rep. Michele Bachmann, MN-06) Staff Asst./Leg. Corr.(Rep. Dennis Hastert, IL-14)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023